http://www.acc.org/Feed?clinicalTopicID=a91761fa-5431-434b-b7d3-9c8977ea5d76 Clinical Topic Feed: Homozygous Familial Hypercholesterolemia en /Latest-in-Cardiology/Articles/2026/03/25/21/27/mon-1045am-coralreef-acc-2026 The novel PCSK9 oral inhibitor enlicitide effectively lowered LDL-C in adults already being treated with statins, demonstrating a potential role as an add-on option for patients not meeting LDL-C goals, according to results from the CORALreef AddOn trial presented during an Investigative Horizons session at ACC.26 in New Orleans and simultaneously published in JACC. 1774885560000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/24/18/20/ACC-Scientific-Statement-Highlights-Emerging-Role-of-Gene-Editing A new ACC Scientific Statement outlines the rapidly evolving landscape of gene-editing therapies and their growing relevance to cardiovascular disease, offering clinicians an overview of both the promise and the challenges of this transformative technology. 1774536660000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/01/20/18/24/Anti-ANGPTL3-Antibody SHR-1918, a fully human monoclonal antibody targeting angiopoietinlike 3 (ANGPTL3), was associated with a manageable safety profile and substantial reduction in LDL-C in patients with homozygous familiar hypercholesterolemia (HoFH) already taking stable lipid-lowering therapy... 1768998600000 Articles and Stories /Latest-in-Cardiology/Articles/2025/11/25/17/05/eagles-eye-view-03dec2025 In this week’s View, Dr. Eagle looks at the potential for electrophysiology (EP) ablation in ambulatory care. He then explores several new studies that reveal the rising rates of heart failure and hypertension. 1764769080000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2025/11/26/14/25/New-Studies-Reveal-Rising-Rates-of-HF-and-HBP The prevalence of heart failure (HF) and hypertension, respectively, are on the rise among U.S. adults, according to two separate studies published in JACC that use data from the National Health and Nutrition Examination Survey (NHANES). 1764170460000 Articles and Stories /Latest-in-Cardiology/Articles/2025/11/06/13/19/JACC-Journals-Publish-Latest-Science-From-aha-2025 AHA 2025 features key science simultaneously published across ACC's JACC Journals, including JACC, JACC: CardioOncology, JACC: Advances, JACC: Case Reports, JACC: Heart Failure and JACC: Cardiovascular Imaging. 1762527600000 Articles and Stories /Latest-in-Cardiology/Articles/2025/10/01/18/04/CVD Risk New immigrants to the U.S. have a lower prevalence of cardiovascular disease risk factors than individuals born in the U.S., but these risk factors increase the longer they live in the U.S., a so-called "healthy immigrant effect," according to research presented during the ACC Middle East 2025 Together with 16th Emirates Cardiac Society Conference, held in Dubai, UAE. 1759414560000 Articles and Stories /Latest-in-Cardiology/Articles/2025/05/27/10/55/Emerging-Gene-Therapies-For-Familial-Hypercholesterolemia Given advancements in the understanding of the genetic underpinnings of several cardiovascular diseases (CVDs), there is an increased focus on the use of targeted gene therapies in the treatment of some of these conditions. 1748362620000 Articles and Stories /Latest-in-Cardiology/Articles/2024/11/13/21/17/mon-314pm-combo-lipid-aha-2024 Advances in lipid therapeutics were the focus of a late-breaking science session at AHA 2024, with researchers presenting findings evaluating the safety of the novel new drug muvalaplin in lowering high levels of lipoprotein(a) [Lp(a)]... 1731960840000 Articles and Stories /Latest-in-Cardiology/Clinical-Trials/2024/10/15/12/46/remain-1 The goal of the REMAIN-1 trial was to assess the lipid-lowering efficacy and safety of recaticimab, a long-acting monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). 1729018020000 Articles and Stories